DDrare: Database of Drug Development for Rare Diseases

Searched query = "Progressive multifocal leukoencephalopathy", "PML", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 111JC101; CYT107; Cidofovir; Collection of blood and urine; Cytarabine; Diagnostic Test: Brain MRI; Didanosine; Emtricitabine; Enfuvirtide; Filgrastim; Interferon alfa; Interferon alfa-2b; Interleukin-7; Lariam; MEFLOQUINE; METHYLPREDNISOLONE; Mefloquine; Methylprednisolone; Neurological evaluation; PREDNISOLONE; Pembrolizumab; Prednisolone; Probenecid; PyVST; Recombinant human interleukin-7; Spinal tap; Tenofovir; Tenofovir-Emtricitabine; Teriflunomide; Topotecan; Tysabri; Zalcitabine; Zidovudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03399981 (ClinicalTrials.gov)	January 24, 2018	9/1/2018	Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries	An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri	Progressive Multifocal Leukoencephalopathy	Biological: Tysabri	Biogen	NULL	Active, not recruiting	N/A	N/A	All	72600		United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03399981
(ClinicalTrials.gov)

January 24, 2018

9/1/2018

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri

Progressive Multifocal Leukoencephalopathy

Biological: Tysabri

Biogen

NULL

Active, not recruiting

N/A

All

72600

United States